GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (STU:6LJ) » Definitions » Quick Ratio

Matinas BioPharma Holdings (STU:6LJ) Quick Ratio : 5.15 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Matinas BioPharma Holdings Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Matinas BioPharma Holdings's quick ratio for the quarter that ended in Mar. 2024 was 5.15.

Matinas BioPharma Holdings has a quick ratio of 5.15. It generally indicates good short-term financial strength.

The historical rank and industry rank for Matinas BioPharma Holdings's Quick Ratio or its related term are showing as below:

STU:6LJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.58   Med: 7.62   Max: 29.1
Current: 5.15

During the past 11 years, Matinas BioPharma Holdings's highest Quick Ratio was 29.10. The lowest was 0.58. And the median was 7.62.

STU:6LJ's Quick Ratio is ranked better than
61.47% of 1539 companies
in the Biotechnology industry
Industry Median: 3.58 vs STU:6LJ: 5.15

Matinas BioPharma Holdings Quick Ratio Historical Data

The historical data trend for Matinas BioPharma Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Quick Ratio Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.66 17.25 11.73 8.06 5.93

Matinas BioPharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.88 9.27 6.19 5.93 5.15

Competitive Comparison of Matinas BioPharma Holdings's Quick Ratio

For the Biotechnology subindustry, Matinas BioPharma Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Quick Ratio falls into.



Matinas BioPharma Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Matinas BioPharma Holdings's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(14.253-0)/2.404
=5.93

Matinas BioPharma Holdings's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(9.466-0)/1.838
=5.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Matinas BioPharma Holdings  (STU:6LJ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Matinas BioPharma Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (STU:6LJ) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.

Matinas BioPharma Holdings (STU:6LJ) Headlines

No Headlines